Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference
01 Februar 2024 - 1:00PM
Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a
commercial-stage biotechnology company, today announced that the
Company will participate in the Guggenheim 6th Annual Biotechnology
Conference, which takes place in New York on February 7-8.
Krish S. Krishnan, Chairman and Chief Executive Officer, will
participate in a fireside chat at 10 am ET during the conference
and host investor meetings on February 7.
A webcast of the presentation will be available here beginning
at 10 am ET on Wednesday, February 7 and will be posted on the
Investors section of the Company’s website.
About Krystal Biotech, Inc.Krystal Biotech,
Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company
focused on the discovery, development and commercialization of
genetic medicines to treat diseases with high unmet medical needs.
VYJUVEK® is the Company’s first commercial product, the first-ever
redosable gene therapy, and the first medicine approved by the FDA
for the treatment of dystrophic epidermolysis bullosa. The Company
is rapidly advancing a robust preclinical and clinical pipeline of
investigational genetic medicines in respiratory, oncology,
dermatology, ophthalmology, and aesthetics. Krystal Biotech is
headquartered in Pittsburgh, Pennsylvania. For more information,
please visit http://www.krystalbio.com, and follow @KrystalBiotech
on LinkedIn and X (formerly Twitter).
CONTACT:
Investors and MediaMeg DodgeKrystal
Biotechmdodge@krystalbio.comSource: Krystal Biotech, Inc.
Krystal Biotech (NASDAQ:KRYS)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
Krystal Biotech (NASDAQ:KRYS)
Historical Stock Chart
Von Sep 2023 bis Sep 2024